Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a review.

摘要: Although lung cancer therapy has slowly improved with standard cytotoxic chemotherapy drugs, we have reached an efficacy plateau. The addition of targeted agents, such as those antiangiogenesis activity, to can improve response and survival outcomes. first these agents gain approval in October 2006 was the antivascular endothelial growth factor antibody, bevacizumab. Small molecule tyrosine kinase inhibitors targeting vascular receptor also proven activity are under active investigation. Vascular disrupting target existing tumor vasculature leading necrosis, being studied solid tumors, including cancer, both single combination chemotherapy. This article will review new antiangiogenic a focus on their use therapeutics.